Evidence map›Paper›PMID 33472405›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2021

Inhibition of T-Cells by Cyclosporine A Reduces Macrophage Accumulation to Regulate Venous Adaptive Remodeling and Increase Arteriovenous Fistula Maturation.

Yutaka Matsubara (松原裕), Gathe Kiwan, Jia Liu (刘佳), Luis Gonzalez, John Langford, Mingjie Gao (高明杰), Xixiang Gao (高喜翔), Ryosuke Taniguchi (谷口良輔), Bogdan Yatsula, Tadashi Furuyama (古山正) and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Human Data First: New Biological Premises for Arteriovenous Fistula Research.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Sustained tenascin-C expression drives neointimal hyperplasia and promotes aortocaval fistula failure.American journal of physiology. Heart and circulatory physiology · 2025
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. The rodent models of arteriovenous fistula.Frontiers in cardiovascular medicine · 2024
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Sex hormones impact early maturation and immune response in the arteriovenous fistula mouse model.American journal of physiology. Heart and circulatory physiology · 2023
    Article
  18. Article
  19. Review
  20. CD206Journal of translational medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Yutaka Matsubara (松原裕)Vascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Gathe KiwanVascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Jia Liu (刘佳)Vascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Luis GonzalezVascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
John LangfordVascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Mingjie Gao (高明杰)Vascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Xixiang Gao (高喜翔)Vascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Ryosuke Taniguchi (谷口良輔)Vascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Bogdan YatsulaVascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Tadashi Furuyama (古山正)Department of Surgery and Sciences, Kyushu University, Fukuoka, Japan (Y.M., T.F.).
Takuya Matsumoto (松本拓也)Department of Vascular Surgery, Kyushu Central Hospital, Fukuoka, Japan (T.M.).
Kimihiro Komori (古森公浩)Division of Vascular Surgery, Department of Surgery, Nagoya University Graduate School of Medicine, Japan (K.K.).
Alan DardikVascular Biology and Therapeutics Program (Y.M., G.K., J. Liu, L.G., J. Langford, M.G., X.G., R.T., B.Y., A.D.), Yale School of Medicine, New Haven, CT.
Yale University · USKyushu University · JPKyushu University Hospital · JPNagoya University · JP

Funding

Short-Term Reserch Training: Students in Health SchoolsT35HL007649 · NHLBI · YALE UNIVERSITY · PI Sarwat I Chaudhry, Erica L Herzog · 1987 to 2026
$5.7M
Manipulating the matrix to improve arteriovenous fistula patencyR01HL144476 · NHLBI · YALE UNIVERSITY · PI Alan Dardik · 2019 to 2026
$5.6M
Research Training in AnesthesiaT32GM086287 · NIGMS · YALE UNIVERSITY · PI ROBERT SCHONBERGER · 2009 to 2026
$3.7M
NHLBI NIH HHS R01 HL144476NHLBI NIH HHS T35 HL007649NIGMS NIH HHS T32 GM086287
6 · The paper itself

Abstract

objectiveArteriovenous fistulae (AVF) are the preferred vascular access for hemodialysis, but the primary success rate of AVF remains poor. Successful AVF maturation requires vascular wall thickening and outward remodeling. A key factor determining successful AVF maturation is inflammation that is characterized by accumulation of both T-cells and macrophages. We have previously shown that anti-inflammatory (M2) macrophages are critically important for vascular wall thickening during venous remodeling; therefore, regulation of macrophage accumulation may be an important mechanism promoting AVF maturation. Since CD4+ T-cells such as T-helper type 1 cells, T-helper type 2 cells, and regulatory T-cells can induce macrophage migration, proliferation, and polarization, we hypothesized that CD4+ T-cells regulate macrophage accumulation to promote AVF maturation. Approach and Results: In a mouse aortocaval fistula model, T-cells temporally precede macrophages in the remodeling AVF wall. CsA (cyclosporine A; 5 mg/kg, sq, daily) or vehicle (5% dimethyl sulfoxide) was administered to inhibit T-cell function during venous remodeling. CsA reduced the numbers of T-helper type 1 cells, T-helper type 2, and regulatory T-cells, as well as M1- and M2-macrophage accumulation in the wall of the remodeling fistula; these effects were associated with reduced vascular wall thickening and increased outward remodeling in wild-type mice. However, these effects were eliminated in nude mice, showing that the effects of CsA on macrophage accumulation and adaptive venous remodeling are T-cell-dependent.

conclusionsT-cells regulate macrophage accumulation in the maturing venous wall to control adaptive remodeling. Regulation of T-cells during AVF maturation may be a strategy that can improve AVF maturation. Graphic Abstract: A graphic abstract is available for this article.

Indexed as

AnimalsArteriovenous Shunt, SurgicalCyclosporineFemaleImmunosuppressive AgentsMacrophagesMaleMiceMice, Inbred C57BLMice, NudeModels, AnimalT-LymphocytesVascular RemodelingCyclosporineImmunosuppressive Agentsarteriovenous fistulacyclosporineinflammationmacrophagesmiceT-lymphocytes

Identifiers

PMID33472405
PMCPMC7904667
OpenAlexW3122211616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.